Year: 2026

VAL-D’OR, Quebec, March 25, 2026 (GLOBE NEWSWIRE) — Cartier Resources Inc. (″ Cartier ″ or the ″ Company ″) (TSXV: ECR; FSE: 6CA) is pleased to announce the tenth batch of results from the 100,000-m drilling program (2 drill rigs) and a new style of gold mineralization (intrusion-related gold deposits) within the underexplored Pontiac sedimentary Group in Hope Sector, on the 100%-owned Cadillac Project, located in Val-d’Or (Abitibi, Quebec). The newly identified largely untested conceptual exploration opportunity is situated immediately south of the prolific Cadillac Fault and supports significant upside potential for large scale gold mineralization typical of porphyry intrusion-related systems in the Pontiac sediments that are reminiscent of the Canadian Malartic Camp. Strategic Highlights from Hope Sector Drill Hole Results (Figures...

SAN JOSE, Calif., March 25, 2026 (GLOBE NEWSWIRE) — zSpace today highlighted the long-standing success of its immersive augmented and virtual reality learning platform across Atlanta Public Schools (APS), where students have used AR/VR technology since 2015 to deepen STEM learning and explore career pathways. Over nearly a decade, APS has integrated zSpace immersive learning experiences across elementary, middle, and high school classrooms, giving students hands-on opportunities to explore complex scientific concepts and practice real-world career skills in safe, simulated environments. Atlanta Public Schools has earned national recognition for its innovation in education, including the 2023 District of Distinction by the International Society for Technology in Education (ISTE), District of Distinction designation by zSpace, and...

Covers the use of vafidemstat for treating non-aggressive symptoms of Borderline Personality Disorder (BPD)MADRID, and CAMBRIDGE, Mass., March 25, 2026 (GLOBE NEWSWIRE) — Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its patent application US 17/439,575, entitled “Methods of treating borderline personality disorder”, further strengthening its intellectual property portfolio for vafidemstat, Oryzon’s LSD1 inhibitor in clinical development for the treatment of psychiatric disorders, including borderline personality disorder (BPD). The allowed claims cover the use of LSD1 inhibitors for the treatment of non-aggressive symptoms of BPD,...

NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) — Getty Realty Corp. (NYSE: GTY), a net lease REIT focused on convenience and automotive retail real estate, will release its financial results for the first quarter ended March 31, 2026 after the market closes on Wednesday, April 22, 2026. Getty Realty Corp. will host a conference call and webcast on Thursday, April 23, 2026, at 8:30 a.m. ET. To participate in the call, please dial 1-877-423-9813, or 1-201-689-8573 for international participants, ten minutes before the scheduled start. Participants may also access the call via live webcast by visiting the investors section of the Company’s website at ir.gettyrealty.com. If you cannot participate in the live event, a replay will be available on Thursday, April 23, 2026, beginning at 11:30 a.m. ET through 11:59 p.m. ET, Thursday, May...

LB-102 has potential to be the first benzamide approved for schizophrenia in the U.S. NOVA-2 trial to enroll approximately 460 patients Primary endpoint to evaluate change in PANSS total score at week 6; secondary endpoints to include evaluations of negative symptoms and cognitive performance as well as safety and tolerability Topline data expected in 2H 2027 NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) — LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive major depressive disorder (MDD), and other neuropsychiatric diseases, today announced the initiation of its pivotal Phase 3 trial (NOVA-2) evaluating the efficacy and safety of LB-102 as a treatment for schizophrenia. LB-102, a novel, once-daily,...

Company Joins AASM Foundation Corporate Recognition Program and Sponsors Junior Investigator Research Grant as IHL-42X Advances Toward Potential Oral Treatment for Obstructive Sleep Apnea MELBOURNE, Australia and NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) — Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing combination therapies for high-impact indications, today announced it has entered into a Partnership Agreement with the American Academy of Sleep Medicine (AASM) Foundation. Through this partnership, Incannex has joined the AASM Foundation’s Corporate Recognition Program and will sponsor a Focused Projects Grant for Junior Investigators dedicated to the Diagnosis, Management, and Treatment of Sleep Apnea, to be awarded in 2026. The partnership reflects the Company’s commitment to the...

Collaboration leverages Converge Bio’s proprietary generative AI to design and optimize novel tri-specific antibodies for oncology needs AI-driven development strategy designed to significantly accelerate discovery timelines and enhance molecule quality for drug candidates targeting solid tumors REHOVOT, Israel and BOSTON, Mass., March 25, 2026 (GLOBE NEWSWIRE) — Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizing toxicity, today announced a collaboration with Converge Bio, a company known for its leading AI platform for drug discovery and development, to accelerate and enhance Purple Biotech’s next-generation tri-specific antibody platform...

Salt Lake City, UT, March 25, 2026 (GLOBE NEWSWIRE) — Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Vicki Goodman, M.D., will become Recursion’s Chief Medical Officer effective April 6, 2026 as David Mauro, M.D., Ph.D. transitions out of the role. As Recursion advances its pipeline and prepares for key clinical and regulatory milestones, which are consistent with previously communicated expectations, Dr. Goodman brings a rare and differentiated perspective of how to translate scientific promise into successful clinical programs. Her experience spans executive roles in biotech and large pharma, with particular expertise in oncology, as well as experience in clinical practice and as an FDA reviewer. “We are very excited to welcome Dr. Goodman to...

HOLMDEL, N.J., March 25, 2026 (GLOBE NEWSWIRE) — BIO-key International, Inc. (NASDAQ: BKYI), a global leader in Identity and Access Management (IAM) and biometric authentication technologies, will host its 2025 year-end investor call on Tuesday, March 31st at 10 a.m. ET with results issued prior the market opening. Mike DePasquale, Chairman & CEO and Cecilia Welch, CFO will lead the conference call and Q&A session.Call Details  Date / Time: Tuesday, March 31st at 10 a.m. ETCall Dial In #: 1-877-418-5460 U.S. or 1-412-717-9594 Int’lLive Webcast / Replay: Webcast & Replay Link – Available for 3 months.Audio Replay: 1-855-669-9658 U.S. or 1-412-317-0088 Int’l; code 4802902About BIO-key International, Inc. (www.BIO-key.com)BIO-key is revolutionizing authentication and cybersecurity with biometric-centric,...

25 March 2026 Announcement no. 3 Pharma Equity Group A/S – Annual Report 2025 Pharma Equity Group A/S – Annual Report 2025 – Highlights of the year Today, the Board of Directors of Pharma Equity Group A/S reviewed and approved the Company’s Annual Report for 2025, the key highlights of which are as follows:In 2025, Reponex Pharmaceuticals A/S obtained regulatory approval to initiate a pivotal Phase 2 trial of RNX-011 for the treatment of secondary bacterial peritonitis. In 2025, RNX-051 was further advanced through continued development work, further maturation of the formulation and continued dialogue with potential industrial partners. The Company is engaged in advanced and constructive discussions with potential partners regarding RNX-051, and, if progress continues as expected, these discussions are expected to be concluded...